ASH 2018 News - Episode 3

OncLive News Network On Location: In San Diego Monday, December 3


We are on site at the San Diego Convention Center in California at the 2018 ASH Annual Meeting!

We have recapped the top news each day during the meeting—and soon we’ll speak with Dr Owen O’Connor on some encouraging lymphoma abstracts, Dr William Wierda on exciting chronic lymphocytic leukemia studies, and Dr Brad Kahl on the latest in non-Hodgkin lymphoma.

Welcome to OncLive News Network! I’m Gina Columbus.

In acute myeloid leukemia, results of the phase III QUANTUM-R trial confirmed that single-agent quizartinib improves survival over salvage chemotherapy therapy in patients with relapsed/refractory FLT3-ITD disease.

Quizartinib also demonstrated a favorable safety profile in this randomized controlled trial.


Data from part 2 of the STORM trial evaluating selinexor in patients with penta-refractory multiple myeloma showed that the agent, when added to low-dose dexamethasone, has clinical activity with rapid and deep responses.

The adverse events associated with this regimen can be effectively managed with dose modifications and supportive care. Selinexor could be a potential option for patients with penta-refractory myeloma who have already received available therapies.


In chronic lymphocytic leukemia, phase III data from the MURANO trial showed that the combination of venetoclax and rituximab had higher peripheral blood undetectable minimal residual disease rate versus bendamustine and rituximab in patients with relapsed/refractory disease. This was also observed in high-risk subgroups.

These data are the first to demonstrate the value of peripheral blood MRD as a predictive marker of clinical outcome for the fixed-duration chemotherapy-free regimen.


Findings from the phase III ILLUMINATE trial demonstrated that the combination of ibrutinib and obinutuzumab had a significant improvement in progression-free survival versus chemoimmunotherapy treatment with chrolambucil and obinutuzumab in patients with chronic lymphocytic leukemia. The benefit was also observed in a high-risk patient population.

Additionally, response rates and depth of remission were also higher with the ibrutinib regimen, which was also found to have a tolerable safety profile.


That’s all for today. Please visit to watch our prior episodes from this meeting.

Thank you for watching OncLive News Network: On Location from the 2018 ASH Annual Meeting in San Diego, California! I’m Gina Columbus.